中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 3
Mar.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(3): 600-605

Application of magnetic resonance imaging-proton density fat fraction in liver fat quantification

DOI: 10.12449/JCH240327
  • 1.

    Department of Liver Cirrhosis，Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine/Institute of Liver Diseases，Shanghai University of Traditional Chinese Medicine，Shanghai 201203，China

  • 2.

    Key Laboratory of Liver and Kidney Diseases，Ministry of Education，Shanghai 201203，China

Research funding:

Shanghai Municipal Science and Technology Commission 2019 “Science and Technology Innovation Action Plan” （Clinical Medicine） (19401972700)

More Information
  • Corresponding author: ZHANG Hua， lnutcmzh@126.com （ORCID： 0000-0001-5926-0999）
  • Received Date: 2023-08-08
  • Accepted Date: 2023-08-28
  • Published Date: 2024-03-20
    Abstract
  • Hepatic steatosis can be observed in chronic liver diseases of different etiologies. The main predisposing factors for hepatic steatosis include chronic viral hepatitis， cholestatic liver disease， alcoholic liver disease， and nonalcoholic fatty liver disease. Simple fatty liver disease is the initial manifestation of hepatic steatosis， followed by steatohepatitis， liver fibrosis， liver cirrhosis， and even hepatocellular carcinoma. With the development of medical imaging technology， magnetic resonance imaging-proton density fat fraction （MRI-PDFF） has been widely used in the diagnosis of fatty liver disease （FLD） in clinical practice. MRI-PDFF is gradually becoming the gold standard for the noninvasive diagnosis of FLD due to its high accuracy and good repeatability. This article reviews the clinical application of MRI-PDFF in liver fat quantification and related research advances.

     

    • FullText(HTML)
  • loading
    • References(46)
  • [1]
    POWELL EE, JONSSON JR, CLOUSTON AD. Steatosis: co-factor in other liver diseases[J]. Hepatology, 2005, 42( 1): 5- 13. DOI: 10.1002/hep.20750.
    [2]
    TAMAKI N, AJMERA V, LOOMBA R. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD[J]. Nat Rev Endocrinol, 2022, 18( 1): 55- 66. DOI: 10.1038/s41574-021-00584-0.
    [3]
    RATZIU V, CHARLOTTE F, HEURTIER A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease[J]. Gastroenterology, 2005, 128( 7): 1898- 1906. DOI: 10.1053/j.gastro.2005.03.084.
    [4]
    BOHTE AE, van WERVEN JR, BIPAT S, et al. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis[J]. Eur Radiol, 2011, 21( 1): 87- 97. DOI: 10.1007/s00330-010-1905-5.
    [5]
    JOHNSTON RJ, STAMM ER, LEWIN JM, et al. Diagnosis of fatty infiltration of the liver on contrast enhanced CT: Limitations of liver-minus-spleen attenuation difference measurements[J]. Abdom Imaging, 1998, 23( 4): 409- 415. DOI: 10.1007/s002619900370.
    [6]
    FISCHER MA, GNANNT R, RAPTIS D, et al. Quantification of liver fat in the presence of iron and iodine: an ex-vivo dual-energy CT study[J]. Invest Radiol, 2011, 46( 6): 351- 358. DOI: 10.1097/RLI.0b013e31820e1486.
    [7]
    CHO YS, LIM S, KIM Y, et al. Abdominal wall thickness affects liver stiffness measurements by 2-D shear wave elastography in patients with chronic liver disease[J]. Ultrasound Med Biol, 2019, 45( 10): 2697- 2703. DOI: 10.1016/j.ultrasmedbio.2019.06.415.
    [8]
    MU R, LU LG. Advances in the application of magnetic resonance imaging in hepatic fat quantification in patients with nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2020, 36( 6): 1366- 1369. DOI: 10.3969/j.issn.1001-5256.2020.06.038.

    穆容, 陆伦根. 磁共振成像技术在非酒精性脂肪性肝病肝脂肪定量中的应用[J]. 临床肝胆病杂志, 2020, 36( 6): 1366- 1369. DOI: 10.3969/j.issn.1001-5256.2020.06.038.
    [9]
    European Association for the Study of the Liver(EASL), European Association for the Study of Diabetes(EASD), European Association for the Study of Obesity(EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease[J]. Obes Facts, 2016, 9( 2): 65- 90. DOI: 10.1159/000443344.
    [10]
    STERN C, CASTERA L. Non-invasive diagnosis of hepatic steatosis[J]. Hepatol Int, 2017, 11( 1): 70- 78. DOI: 10.1007/s12072-016-9772-z.
    [11]
    RUNGE JH, SMITS LP, VERHEIJ J, et al. MR spectroscopy-derived proton density fat fraction is superior to controlled attenuation parameter for detecting and grading hepatic steatosis[J]. Radiology, 2017: 162931. DOI: 10. 1148/radiol. 2017162931.
    [12]
    GUO D, YANG C. Progress in MRI research on fatty liver[J]. Med J West China, 2017, 29( 4): 419- 422.

    郭达, 杨陈. 脂肪肝的MRI研究进展[J]. 西部医学, 2017, 29( 4): 419- 422.
    [13]
    CAUSSY C, REEDER SB, SIRLIN CB, et al. Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials[J]. Hepatology, 2018, 68( 2): 763- 772. DOI: 10.1002/hep.29797.
    [14]
    BANNAS P, KRAMER H, HERNANDO D, et al. Quantitative magnetic resonance imaging of hepatic steatosis: Validation in ex vivo human livers[J]. Hepatology, 2015, 62( 5): 1444- 1455. DOI: 10.1002/hep.28012.
    [15]
    REEDER SB, HU HH, SIRLIN CB. Proton density fat-fraction: a standardized MR-based biomarker of tissue fat concentration[J]. J Magn Reson Imaging, 2012, 36( 5): 1011- 1014. DOI: 10.1002/jmri.23741.
    [16]
    MAMIDIPALLI A, FOWLER KJ, HAMILTON G, et al. Prospective comparison of longitudinal change in hepatic proton density fat fraction(PDFF) estimated by magnitude-based MRI(MRI-M) and complex-based MRI(MRI-C)[J]. Eur Radiol, 2020, 30( 9): 5120- 5129. DOI: 10.1007/s00330-020-06858-x.
    [17]
    HERNANDO D, SHARMA SD, ALIYARI GHASABEH M, et al. Multisite, multivendor validation of the accuracy and reproducibility of proton-density fat-fraction quantification at 1.5T and 3T using a fat-water phantom[J]. Magn Reson Med, 2017, 77( 4): 1516- 1524. DOI: 10.1002/mrm.26228.
    [18]
    YOSHIZAWA E, YAMADA A. MRI-derived proton density fat fraction[J]. J Med Ultrason(2001), 2021, 48( 4): 497- 506. DOI: 10.1007/s10396-021-01135-w.
    [19]
    VU KN, GILBERT G, CHALUT M, et al. MRI-determined liver proton density fat fraction, with MRS validation: Comparison of regions of interest sampling methods in patients with type 2 diabetes[J]. J Magn Reson Imaging, 2016, 43( 5): 1090- 1099. DOI: 10.1002/jmri.25083.
    [20]
    SATKUNASINGHAM J, HOSSEINI NIK H, Fischer S, et al. Can negligible hepatic steatosis determined by MRI-proton density fat fraction obviate the need for liver biopsy in potential liver donors?[J]. Liver Transpl, 2018, 24( 4): 470- 477. DOI: 10. 1002/lt. 24965.
    [21]
    CAMPO CA, HERNANDO D, SCHUBERT T, et al. Standardized approach for roi-based measurements of proton density fat fraction and R2* in the liver[J]. AJR Am J Roentgenol, 2017, 209( 3): 592- 603. DOI: 10.2214/AJR.17.17812.
    [22]
    LU WT, SHI HL, CHEN QL, et al. Distribution characteristics of MRI-PDFF in patients with metabolic related fatty liver disease[J/CD]. Chin J Clinicians: Electronic Edition, 2021, 15( 7): 503- 508. DOI: 10.3877/cma.j.issn.1674-0785.2021.07.005.

    陆玮婷, 史会连, 陈沁磊, 等. 代谢相关脂肪性肝病患者MRI-PDFF分布特点[J/CD]. 中华临床医师杂志: 电子版, 2021, 15( 7): 503- 508. DOI: 10.3877/cma.j.issn.1674-0785.2021.07.005.
    [23]
    PERMUTT Z, LE TA, PETERSON MR, et al. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease- MRI accurately quantifies hepatic steatosis in NAFLD[J]. Aliment Pharmacol Ther, 2012, 36( 1): 22- 29. DOI: 10.1111/j.1365-2036.2012.05121.x.
    [24]
    SHAO CX, YE J, DONG Z, et al. Steatosis grading consistency between controlled attenuation parameter and MRI-PDFF in monitoring metabolic associated fatty liver disease[J]. Ther Adv Chronic Dis, 2021, 12: 20406223211033119. DOI: 10.1177/20406223211033119.
    [25]
    TAMAKI N, MUNAGANURU N, JUNG J, et al. Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease[J]. Gut, 2022, 71( 5): 983- 990. DOI: 10.1136/gutjnl-2021-324264.
    [26]
    HARRISON SA, BASHIR MR, GUY CD, et al. Resmetirom(MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet, 2019, 394( 10213): 2012- 2024. DOI: 10.1016/S0140-6736(19)32517-6.
    [27]
    PARK CC, NGUYEN P, HERNANDEZ C, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease[J]. Gastroenterology, 2017, 152( 3): 598- 607. e 2. DOI: 10.1053/j.gastro.2016.10.026.
    [28]
    LEE SJ, KIM SU. Noninvasive monitoring of hepatic steatosis: controlled attenuation parameter and magnetic resonance imaging-proton density fat fraction in patients with nonalcoholic fatty liver disease[J]. Expert Rev Gastroenterol Hepatol, 2019, 13( 6): 523- 530. DOI: 10.1080/17474124.2019.1608820.
    [29]
    JAYAKUMAR S, MIDDLETON MS, LAWITZ EJ, et al. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib[J]. J Hepatol, 2019, 70( 1): 133- 141. DOI: 10.1016/j.jhep.2018.09.024.
    [30]
    KIM HJ, CHO HJ, KIM B, et al. Accuracy and precision of proton density fat fraction measurement across field strengths and scan intervals: A phantom and human study[J]. J Magn Reson Imaging, 2019, 50( 1): 305- 314. DOI: 10.1002/jmri.26575.
    [31]
    QI Q, WEINSTOCK AK, CHUPETLOVSK AK, et al. Magnetic resonance imaging-derived proton density fat fraction(MRI-PDFF) is a viable alternative to liver biopsy for steatosis quantification in living liver donor transplantation[J]. Clin Transplant, 2021, 35( 7): e14339. DOI: 10.1111/ctr.14339.
    [32]
    REN H, YANG ZH. Progress in the application of MRI diagnostic techniques related to non-alcoholic fatty liver disease[J]. Radiol Pract, 2020, 35( 7): 928- 932. DOI: 10.13609/j.cnki.1000-0313.2020.07.019.

    任浩, 杨正汉. 非酒精性脂肪肝病相关MRI诊断技术的应用进展[J]. 放射学实践, 2020, 35( 7): 928- 932. DOI: 10.13609/j.cnki.1000-0313.2020.07.019.
    [33]
    MARTÍ-AGUADO D, ALBERICH-BAYARRI Á, MARTÍN-RODRÍGUEZ JL, et al. Differences in multi-echo chemical shift encoded MRI proton density fat fraction estimation based on multifrequency fat peaks selection in non-alcoholic fatty liver disease patients[J]. Clin Radiol, 2020, 75( 11): 880. e5- 880. e 12. DOI: 10.1016/j.crad.2020.07.031.
    [34]
    KIM JW, LEE CH, YANG Z, et al. The spectrum of magnetic resonance imaging proton density fat fraction(MRI-PDFF), magnetic resonance spectroscopy(MRS), and two different histopathologic methods(artificial intelligence vs. pathologist) in quantifying hepatic steatosis[J]. Quant Imaging Med Surg, 2022, 12( 11): 5251- 5262. DOI: 10.21037/qims-22-393.
    [35]
    IDILMAN IS, KESKIN O, CELIK A, et al. A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease[J]. Acta Radiol, 2016, 57( 3): 271- 278. DOI: 10.1177/0284185115580488.
    [36]
    YOKOO T, SERAI S D, PIRASTEH A, et al. Linearity, bias, and precision of hepatic proton density fat fraction measurements by using mr imaging: a meta-analysis[J]. Radiology, 2018, 286( 2): 486- 498. DOI: 10. 1148/radiol. 2017170550.
    [37]
    CHEN G, JIANG J, WANG X, et al. Evaluation of hepatic steatosis before liver transplantation in ex vivo by volumetric quantitative PDFF-MRI[J]. Magn Reson Med, 2021, 85( 5): 2805- 2814. DOI: 10.1002/mrm.28592.
    [38]
    GU J, LIU S, DU S, et al. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis[J]. Eur Radiol, 2019, 29( 7): 3564- 3573. DOI: 10.1007/s00330-019-06072-4.
    [39]
    YANG YM, LIU YP, ZHOU DJ, et, al. The value of 3.0T MRI PDFF and IP-OP in quantitative evaluation of fatty liver[J]. J Jilin Univ(Med Edit), 2020, 46( 4): 875- 880. DOI: 10.13481/j.1671-587x.20200434.

    杨逸铭, 刘玉品, 周懂晶, 等. 3.0T MRI PDFF和IP-OP对脂肪肝定量评估的价值[J]. 吉林大学学报: 医学版, 2020, 46( 4): 875- 880. DOI: 10.13481/j.1671-587x.20200434.
    [40]
    STINE JG, MUNAGANURU N, BARNARD A, et al. Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2021, 19( 11): 2274- 2283. e 5. DOI: 10.1016/j.cgh.2020.08.061.
    [41]
    LU JN, LI YS, WEN Y, et al. Application value of liver/spleen CT value, controlled attenuation parameter,and magnetic resonance imagingproton density fat fraction in chronic hepatitis B patients with hepatic steatosis[J]. J Clin Hepatol, 2024, 40( 1): 46- 51. DOI: 10.12449/JCH240109.

    鲁景楠, 李岩松, 温雅, 等. 肝/脾CT值、CAP和MRI-PDFF在慢性乙型肝炎脂肪变性患者中的应用价值[J]. 临床肝胆病杂志, 2024, 40( 1): 46- 51. DOI: 10.12449/JCH240109.
    [42]
    YANG YM, LIU YP, HUANG LX, et al. Quantitative evaluation of liver fat content in patients with chronic hepatitis B using magnetic resonance proton density fat fraction and transient elastography[J]. J Clin Hepatol, 2021, 37( 12): 2793- 2797. DOI: 10.3969/j.issn.1001-5256.2021.12.013.

    杨逸铭, 刘玉品, 黄丽霞, 等. 磁共振质子密度脂肪分数和瞬时弹性成像对慢性乙型肝炎患者肝脂肪含量的定量评估价值[J]. 临床肝胆病杂志, 2021, 37( 12): 2793- 2797. DOI: 10.3969/j.issn.1001-5256.2021.12.013.
    [43]
    CHO Y, RHEE H, KIM YE, et al. Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial(ESSENTIAL study)[J]. BMC Med, 2022, 20( 1): 93. DOI: 10.1186/s12916-022-02288-2.
    [44]
    LU WT, LIU LN, SHI HL, et al. Clinical study on the treatment of 68 cases of non alcoholic fatty liver disease of liver depression and spleen deficiency type with“Jiuwei Qingzhi Cream”[J]. Jiangsu J Traditi Chin Med, 2022, 54( 7): 33- 36. DOI: 10.19844/j.cnki.1672-397X.

    陆玮婷, 刘丽娜, 史会连, 等.“九味清脂膏”治疗肝郁脾虚型非酒精性脂肪性肝病68例临床研究[J]. 江苏中医药, 2022, 54( 7): 33- 36. DOI: 10.19844/j.cnki.1672-397X.
    [45]
    ALKHOURI N, HERRING R, KABLER H, et al. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial[J]. J Hepatol, 2022, 77( 3): 607- 618. DOI: 10.1016/j.jhep.2022.04.003.
    [46]
    AN ZM, FENG Q. Magnetic resonance imaging-proton density fat fraction: A potential surrogate endpoint for nonalcoholic steatohepatitis clinical trials[J]. J Clin Hepatol, 2021, 37( 6): 1445- 1448. DOI: 10.3969/j.issn.1001-5256.2021.06.047.

    安梓铭, 冯琴. 磁共振质子密度脂肪分数——一种具有潜力的非酒精性脂肪性肝炎临床试验替代终点[J]. 临床肝胆病杂志, 2021, 37( 6): 1445- 1448. DOI: 10.3969/j.issn.1001-5256.2021.06.047.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (696) PDF downloads(110) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return